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Abstract
Background: Periodontitis, which progressively destroys tooth-supporting structures, is one of the most
widespread infectious diseases and the leading cause of tooth loss in adults. Evidence from preclinical trials and
small-scale pilot clinical studies indicates that stem cells derived from periodontal ligament tissues are a promising
therapy for the regeneration of lost/damaged periodontal tissue. This study assessed the safety and feasibility of
using autologous periodontal ligament stem cells (PDLSCs) as an adjuvant to grafting materials in guided tissue
regeneration (GTR) to treat periodontal intrabony defects. Our data provide primary clinical evidence for the efficacy
of cell transplantation in regenerative dentistry.
Methods: We conducted a single-center, randomized trial that used autologous PDLSCs in combination with
bovine-derived bone mineral materials to treat periodontal intrabony defects. Enrolled patients were randomly
assigned to either the Cell group (treatment with GTR and PDLSC sheets in combination with Bio-oss®) or the
Control group (treatment with GTR and Bio-oss® without stem cells). During a 12-month follow-up study, we
evaluated the frequency and extent of adverse events. For the assessment of treatment efficacy, the primary
outcome was based on the magnitude of alveolar bone regeneration following the surgical procedure.
Results: A total of 30 periodontitis patients aged 18 to 65 years (48 testing teeth with periodontal intrabony
defects) who satisfied our inclusion and exclusion criteria were enrolled in the study and randomly assigned to the
Cell group or the Control group. A total of 21 teeth were treated in the Control group and 20 teeth were treated in
the Cell group. All patients received surgery and a clinical evaluation. No clinical safety problems that could be
attributed to the investigational PDLSCs were identified. Each group showed a significant increase in the alveolar
bone height (decrease in the bone-defect depth) over time (p < 0.001). However, no statistically significant
differences were detected between the Cell group and the Control group (p > 0.05).
Conclusions: This study demonstrates that using autologous PDLSCs to treat periodontal intrabony defects is safe
and does not produce significant adverse effects. The efficacy of cell-based periodontal therapy requires further
validation by multicenter, randomized controlled studies with an increased sample size.
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Background
Periodontitis is an inflammatory disease that causes
pathological alterations in tooth-supporting tissues,
which can lead to tooth loss if left untreated. National
surveys have shown that the majority of adults suffer
from moderate periodontitis, and up to 15 % of the
population is affected by severe generalized periodon-
titis at some stage of their lives [1, 2]. The significant
burden of periodontal disease and its impact on general
health and patient quality of life suggest a clinical need
for the effective management of this condition [3–5].
The ultimate goal of periodontal therapy is the predictable
regeneration of the functional attachment apparatus that is
destroyed by periodontitis, which involves at least three
unique tissues, including the cementum, periodontal liga-
ment (PDL), and alveolar bone. To date, several regenera-
tive procedures have been developed in an attempt to treat
periodontitis, including guided tissue regeneration (GTR),
bone graft placement, and the use of bioactive agents, such
as growth factors (reviewed in [5–8]). However, the current
therapeutic techniques used either alone or in combination
have limitations in producing complete and predicable re-
generation, especially in advanced periodontal defects. In
these cases, remaining deep intraosseous defects following
periodontal therapy are high-risk sites for the further pro-
gression of periodontitis (reviewed in [9–11]).
According to histological evidence, the GTR tech-
nique combined with grafting materials, such as Bio-oss®
(Geistlich Pharm. AG, Volhusen, Switzerland) and autolo-
gous bone, is partially effective at treating periodontal
defects; however, the currently available GTR-based ther-
apies remain rudimentary and show poor clinical predict-
ability (reviewed in [7, 8, 11]). Recent advances in stem
cell biology and regenerative medicine have enabled the
use of cell-based therapy in periodontal diseases (reviewed
in [5, 12]). To date, a large number of studies have indi-
cated that ex vivo-manipulated stem cells derived from
either bone marrow or the PDL can be used in conjunc-
tion with different physical matrices (autografts, xeno-
grafts, allografts, and alloplastic materials) to regenerate
periodontal tissues in vivo (reviewed in [13–15]).
Although controversy remains regarding which tissues
provide the most appropriate donor source for cell isola-
tion, there is evidence that the cells of PDL tissues have
the capacity to form a complete periodontal attachment
apparatus (reviewed in [13–15]). The regenerative capacity
of the PDL is attributed to a few progenitor cells within
the PDL that maintain their proliferation and differenti-
ation potential; thus, regeneration of the periodontium
depends on the participation of these mesenchymal
stem/stromal cells (MSCs) (reviewed in [5, 12, 13]).
PDL-derived progenitors are committed to several de-
velopmental lineages, i.e., osteoblastic, fibroblastic and
cementoblastic [16], which suggests that these cells are
capable of regenerating multiple periodontal tissues. In-
deed, positive preclinical results have been achieved in
a wide range of in vitro and in vivo models [17–28].
The next phase of study requires the clinical applica-
tion of these advanced therapies.
Worldwide, periodontitis remains highly prevalent and
leads to a loss of the affected teeth. This disease threatens
the quality of life of the middle-aged population as far as
oral functioning is concerned. Unfortunately, no current
clinical periodontal treatments can heal the defects in the
affected region or regenerate lost periodontal tissue to a
normal structure and functionality. It is clear that there
is a clinical need for such treatments and a vast patient
demand. Importantly, several groups have commenced
small-scale pilot/feasibility studies in humans [21, 29–31];
thus, there is now sufficient information to support en-
deavors to move cell-based periodontal therapy into the
clinical arena. We established a clinical protocol to further
test the safety, feasibility, and potential efficacy of stem cells
for the treatment of periodontal deep intraosseous defects.
Methods
Study design
This study had a randomized design involving one dental
facility (Translational Research Center, School of Stoma-
tology, Fourth Military Medical University) and was con-
ducted in compliance with Good Clinical Practice (GCP)
guidelines according to the schedule shown in Fig. 1. This
clinical trial, including the recruitment of subjects, was
performed from 1 June 2011 to 30 December 2013, and
the study was completed at the end of 2014 with a 1-year
follow-up of the patients. The study protocol for this trial
is provided in Additional file 1.
Ethics
This study was approved by the ethical committees of the
School of Stomatology, Fourth Military Medical University
(2011-02) and is registered with the ClinicalTrials.gov
database (reference no. NCT01357785). This study was
conducted according to the Declaration of Helsinki, and
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all recruited patients consented to participate in this trial
and contribute their trial data for noncommercial pur-
poses. The protocol of this trial was externally reviewed
and approved by an anonymous independent ethical re-
view committee to ensure no serious ethical concerns.
Patients, enrollment and randomization
Patients with periodontitis visiting our dental institution
were requested to participate in the study. In compliance
with GCP guidelines, prospective patients who provided
written informed consent underwent clinical inspection
and an oral cavity diagnosis. We selected subjects who
satisfied the inclusion and exclusion criteria (recorded as
the date of recruitment). The majority of these criteria
were used in previous similar periodontal clinical trials
[32, 33]. The inclusion and exclusion criteria and
methods for randomization are provided in Additional
file 2 (Appendices 1 and 2).
Study products and interventions
The third molars of the patients in the Cell group were
extracted and subjected to cell isolation and transplant
Fig. 1 The flow chart of the trial describes the selection, randomization, treatment and follow-up process. A physician (Investigator 3) performed
the follow-up examination of the patients and remained blinded to the treatment conditions until the clinical trial was completed. GTR Guided
tissue regeneration
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production according to the Good Laboratory Practice
and Good Manufacturing Practice (GMP) guidelines.
The cells were assessed for cell colony-forming ability
and osteogenic/adipogenic differentiation (Fig. 2A). Prior
to the extraction surgery, at least two independent asses-
sors concluded that a tooth (or teeth) extraction was re-
quired due to impacted or nonfunctional reasons. The
methods for cell isolation and characterization are pre-
sented in Additional file 2 (Appendix 3). The PDL cell
sheets obtained from the patient’s own tooth/teeth (see
inclusion criteria) were produced using the Good Labora-
tory Practice and GMP guidelines using a standardized
procedure in the Research and Development Center for
Tissue Engineering (Fourth Military Medical University,
145th West Chang-le Road, Xi’an 710032, Shaanxi, Peo-
ple’s Republic of China). The detailed method is de-
scribed in Additional file 2 (Appendix 3). Bio-Oss® and
Bio-Guide® were purchased from Geistlich Pharma AG
(Volhusen, Switzerland). Both transplants (Bio-oss® only or
Bio-oss®/cell sheets) were freshly prepared by laboratory
researchers (Fig. 2B a–c). Investigator 3, who per-
formed the follow-up study, was kept blinded to the
treatment conditions until the study was completed.
For the surgical treatment, Bio-oss® only (Control
group) or Bio-oss®/cell sheets (Cell group) were admin-
istered only to the bony defect region (Fig. 2B d–f ). Each
subject received a standard initial preparation, including
oral hygiene instruction, full-mouth scaling, and root
planning before surgical treatment, in order to minimize
the bacterial insult and reduce variability between lesions
at baseline. The operations were performed using GCP
procedures. A 12-month postoperative follow-up was per-
formed for each patient.
Safety assessment
A cell safety assessment was performed to detect chromo-
somal karyotype changes between freshly isolated peri-
odontal ligament stem cells (PDLSCs) and those obtained
from the cell sheets (the latter underwent approxi-
mately 30-day ex-vivo cultures). The detailed methods
are described in Additional file 2 (Appendix 3). Compli-
cations and adverse events during postoperative healing
were recorded, and we examined the extent of adverse
event occurrence. In addition, blood was obtained from
patients preoperatively and at 2 weeks, 3 months and
12 months postoperatively. Blood examinations in-
cluded: (i) a decrease in the white blood cell count; (ii)
an increase in the red blood cell count; (iii) a decrease/
increase in the percentage of neutrophils; (iv) a de-
crease/increase in the percentage of lymphocytes; (v) an
increase in blood bilirubin; (vi) a decrease in blood
lactate dehydrogenase; (vii) an increase in C-reactive
protein; and (viii) an increase in creatinine phosphoki-
nase. Moreover, the levels of IgA, IgG, IgM, C3 and C4
Fig. 2 Cell isolation, characterization and surgery. A The impacted third molar of patients was extracted and subjected to cell isolation and cell
characterization for cell colony-forming ability and osteogenic/adipogenic differentiation. B The production of cell sheet/scaffold transplants and
in vivo transplantation, including: (a) cell sheet formation; (b) Bio-Oss® particulates; (c) cell sheet/scaffold transplants; (d) exposure of bone defects;
(e) placement of transplants; and (f) closure of the flap
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were measured in the serum using enzyme-linked
immunosorbent assay (ELISA) at the Department of
Clinical Laboratory, Fourth Military Medical University
School of Stomatology. At the time of blood collection,
the urine of each patient was collected and assessed for:
(i) a positive test for glucose/albumin; (ii) an increase in
β-N-acetyl-D-glucosaminidase; and (iii) an increase in
β2 microglobulin.
Efficacy assessment
The main outcome measure in the study protocol was the
rate of increase in alveolar bone height at 3, 6 and 12
months postoperation (primary outcome). The bone-defect
depth (the distance in millimeters from the deepest part
of the defect to the cementoenamel junction of the
tooth) was measured as described in Additional file 2
(Appendix 4) [34]. The clinical attachment level (CAL),
probing depth (PD) and gingival recession (GR) mea-
sured in millimeters are generally used to assess path-
ology in periodontal disease. However, these parameters
do not directly assess the efficacy of cells in periodontal
tissue regeneration and were selected as secondary out-
come measures to ascertain if the cells caused abnor-
mal periodontal healing following periodontal surgery.
The methods for the determination of these parameters
at baseline and 3 months postoperation are described
in Additional file 2 (Appendix 4) [32, 33].
Statistics
This study was performed using a per-protocol analysis.
In this analysis, all of the randomized teeth received at
least one therapy, but the teeth that did not receive
treatment were excluded (modified per-protocol ana-
lysis). The last-observation-carried-forward method was
used for the per-protocol analysis. The missing data
points were input into the postbaseline follow-up visits
from the last observation available for each patient. For
analysis, we employed SAS version 8.2 software (SAS
Institute Inc., Carey, North Carolina, USA). The per-
protocol set analysis was performed for the primary out-
come. The baseline between-group comparisons in age
and clinical examination indices were performed using
independent group t tests. The between-group compari-
son of sex was performed using the Fisher’s exact prob-
ability test. The changes in clinical examination indices
were tested using a repeated-measures analysis of vari-




The flow diagram for the study is shown in Fig. 3. A total
of 48 screened teeth were randomly assigned to either the
Control group or the Cell group. However, only 41 teeth
received surgery (21 teeth in the Control group and 20
teeth in the Cell group). The baseline measurements of
the teeth are shown in Table 1. A Fisher’s exact probability
test found no significant between-group differences in the
donors who provided teeth for randomization and testing.
Cell culture and surgery
In this trial, patients who had at least one tooth (e.g.,
wisdom tooth) that needed to be extracted due to im-
paction or nonfunctional reasons and agreed to the
tooth extraction were enrolled. Prior to extraction sur-
gery, at least two independent assessors concluded that a
tooth or teeth required extraction. The extracted teeth
were used for cell isolation. Only two teeth failed during
the cell isolation step, and the corresponding two patients
were excluded from further study. All of the cells exhib-
ited colony-forming ability. In addition, these cells were
positive for the MSC markers STRO-1, CD146, CD105,
CD29, and CD90 and negative for the hematopoietic
markers CD31 and CD45. The cells were successfully dif-
ferentiated in osteogenic and adipogenic microenviron-
ments and subsequently used for cell sheet production
and periodontal surgery (refer to Additional file 2 (Appen-
dix 3) for more information).
Safety evaluation
Postoperative healing occurred without significant prob-
lems, and none of the patients reported any complica-
tions/adverse events other than medium-sized swelling
and pain. None of the pain experienced by patients re-
quired therapy. All of the patients underwent blood and
urine tests preoperatively and at 2 weeks, 3 months and
12 months postoperatively. Changes in the white/red
blood cell count, percentage of neutrophils/lymphocytes,
and blood bilirubin/lactate dehydrogenase/C-reactive pro-
tein/creatinine phosphokinase levels were within the clin-
ically accepted range (no measurement exceeded its
clinical reference value). Importantly, no significant
changes in IgA, IgG, IgM, C3 or C4 concentrations
were found in the serum of any of the patients. A urine
test showed that one patient (with one tooth that re-
ceived GTR and Bio-oss® therapy without stem cells)
was positive for glucose (this patient was ultimately not
diagnosed with diabetes mellitus) and two patients were
positive for albumin (each patient had two teeth in-
volved in this trial, and one tooth per patient received
cell therapy). No significant changes in urinary β-N-
acetyl-D-glucosaminidase or β2 microglobulin were
found for any of the patients.
Evaluation of efficacy
Patient demographic data and the baseline measurements
of the affected teeth are shown in Table 1. All of the
treated teeth in both groups adequately recovered
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Fig. 3 The flow diagram of the trial
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following surgery. There was no loss of treated teeth dur-
ing this trial. X-ray examinations showed significant bone
fill in both groups (Fig. 4). The magnitude of increase in
alveolar bone height at 3, 6 and 12 months (bone fill over
time) was determined as the decrease in the bone-defect
depth. Each group showed a significant increase in the al-
veolar bone height over time (p < 0.001). However, no sta-
tistically significant differences were found between the
Cell group and the Control group (p > 0.05) (Table 2). Re-
garding the clinical periodontal parameters, no statistically
significant differences were found for the increased CAL,
PD or GR between the Cell and Control groups at 3
months postsurgery (p > 0.05) (Table 3).
Discussion
Although there are a number of clinical techniques avail-
able for the management of periodontal intrabony defects,
clinicians continue to seek more predictable regenerative
therapies that are less technique-sensitive, lead to rapid
tissue regeneration, and applicable to the broad array of
periodontal conditions that are encountered daily in the
clinic. Recent evidence from animal models [17–28] and
several small-scale pilot/feasibility studies [21, 29–31] in-
dicates that ex vivo-cultured PDL cells may serve as a
powerful tool for periodontal therapy. A number of animal
studies have provided an overwhelming body of evidence
that MSCs can be safely and effectively used for periodon-
tal regeneration (reviewed in [12]). As a consequence of
these successful animal studies, the clinical application of
Fig. 4 Radiographic evidence for bone height increases in the Control group and the Cell group (black arrowheads points to sites of bone
defect in each radiograph)
Table 1 Teeth and baseline
Control group Cell group p value
Sex (n) 21 20 0.134a
Male (n) 6 2
Female (n) 15 18
Age (years, mean ± SE) 30.04 ± 7.90 26.05 ± 4.44 0.053b
CAL (mm, mean ± SE) 5.28 ± 1.60 5.15 ± 1.52 0.795b
BDD (mm, mean ± SE) 7.19 ± 1.87 7.20 ± 2.65 0.990b
PD (mm, mean ± SE)
Facial 5.68 ± 1.59 6.43 ± 1.92 0.185b
Lingua (palatal) 5. 86 ± 1.43 6.25 ± 1.36 0.373b
GR (mm, median (interquartile range))
Facial 0.33 (1.0) 0.692c
Lingua (palatal) 0.33 (0.83) 0.320c
aFisher’s exact probability test; bindependent group t test; cMann-Whitney test.
BDD bone-defect depth, CAL clinical attachment levels, GR gingival recession,
PD probe depth, SE standard error
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stem cells for the regeneration of periodontal tissue has
begun [30, 31].
Substantial evidence suggests that it is time is to move
cell-based periodontal therapy from animal studies to
human clinical trials. However, there are critical steps in
moving this field towards human clinical utility. In
addition to clinical efficacy, the safety of cell-based ther-
apies has not been fully evaluated, and the risks of stem
cell therapies have been underscored by several clini-
cians and researchers. Moreover, issues, such as cell de-
livery, cell immunogenicity, use of autologous cells or
allogeneic cells, control of cell fates in vitro and in vivo,
and cost-effectiveness, are all important considerations
that should be addressed before this therapy can move
forward [35–39]. The next critical phase requires the
identification of tissues that provide the most appropri-
ate donor source(s) and the systematic validation of
these specific MSCs as reliable for periodontal cytothera-
peutic use. Furthermore, the establishment of large-scale
preparation facilities incorporating the stringent protocols
of GMP will be an absolute necessity. Regulatory agencies
need to define new criteria to evaluate the risk associated
with specific stem cells and their differentiated progeny
(reviewed in [35, 36]). The purpose of this trial was to pro-
vide evidence for the use of ex vivo-cultured cells to treat
periodontitis and determine the best approach to treat this
disease.
For incurable and life-threatening diseases, such as
diabetes, Parkinson’s, muscular dystrophy, Alzheimer’s,
neural and cardiac diseases and refractory systemic lupus
erythematosus, cell-based therapy is more likely to be
warranted and accepted by the government and patients
[37–39]. However, periodontal tissue regeneration using
cell therapy is not yet economically viable or competitive
with current root canal therapies and dental implants.
Due to the non-life threatening nature of periodontitis,
periodontal tissues have not been considered to be a major
target for stem cell-based regenerative medical research.
Nevertheless, affected teeth are ideal for the evaluation of
new therapies because the patients are not usually ill.
Thus, if anything goes wrong with the treatment, the situ-
ation is far less likely to be life threatening. Furthermore,
the accessibility of teeth facilitates treatments that do not
require major surgery [40].
In a previous study by Feng et al., periodontitis patients
were treated with the local administration of autologous
PDL or gingival stem cells. Neither adverse reactions nor
an increase in any autoantibodies was observed; however,
only three cases were observed long-term [30]. To move
cell-based periodontal therapy from preclinical study and
case report into clinical trials, we conducted this study to
evaluate the safety and primary efficacy of this treatment.
The results of this study have implications for oral health
care resourcing and may facilitate improvements in the
Table 2 Bone-defect depth with time (the distance from the deepest part of the defect to the cementoenamel junction of the
tooth in mm, mean ± standard error)
No. of teeth Baseline 3 months 6 months 12 months F value p value
Control group 21 7.19 ± 1.87 4.81 ± 1.93 5.11 ± 1.53 4.80 ± 1.41 0.11 0.742a
Cell group 20 7.20 ± 2.65 4.89 ± 1.73 4.61 ± 1.87 4.49 ± 2.03
aRepeated-measures analysis of variance
Table 3 Changes in clinical examination indices over time (mm, mean ± standard error)
No. of teeth Baseline 3 months F value p value
CAL
Control group 21 5.28 ± 1.60 5.07 ± 1.48 0.817 0.371a
Cell group 20 5.15 ± 1.52 4.42 ± 1.19
PD
Control group 21 Buccal 5.68 ± 1.59 3.88 ± 0.77 0.962 0.333a
Cell group 20 Buccal 6.43 ± 1.92 3.80 ± 1.03
Control group 21 Lingual or palatal 5. 86 ± 1.43 3.79 ± 0.55 2.191 0.147a
Cell group 20 Lingual or palatal 6.25 ± 1.36 4.20 ± 0.86
GR
Control group 21 Buccal 0.62 ± 0.89 1.54 ± 0.96 0.133 0.728a
Cell group 20 Buccal 0.70 ± 1.09 1.28 ± 0.82
Control group 21 Lingual or palatal 0.52 ± 0.85 1.38 ± 1.37 0.012 0.915a
Cell group 20 Lingual or palatal 0.73 ± 0.87 1.23 ± 0.92
aRepeated-measures analysis of variance. CAL clinical attachment levels, PD probe depth, GR gingival recession
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treatment of people with periodontitis. No clinical safety
problems attributable to the investigational PDLSCs were
identified in our study. Each group showed a significant
increase in alveolar bone height over time (p < 0.001;
Table 2). Although no statistically significant differences
were found for the outcomes in the bone and clinical pa-
rameters between the Cell and Control groups (p > 0.05;
Tables 2 and 3), the results of this study were the first to
show that cell-based interventions are safe for human
dental use in trials. Geistlich Bio-Oss® is a natural bone
substitute with osteoconductive properties; however, there
is no substantial evidence that this product will lead to ef-
fective or predictable bone regeneration in periodontal
intrabony defects. Because Bio-Oss® particles may become
an integral part of the newly formed bone framework and
preserve volume over time [41], the use of this material as
a scaffold for PDLSCs requires further investigation. Previ-
ous studies showed that allogeneic bone matrix may re-
generate new bone, new cementum, and a new PDL
around teeth that were previously contaminated by bacter-
ial plaque [42, 43]. Human-derived biomaterials would be
the first choice as a cell carrier in similar future trials [44].
Nevertheless, the results that were obtained in this study
may have important implications for the design of more
appropriate cell-delivery materials to test cell therapies in
patients with periodontitis.
The study presented here used central randomization,
which is a strict and complete randomization method that
ensures adequate concealment. The surgeon and the in-
vestigator who collected the baseline and follow-up data
worked independently in this trial. Throughout the entire
trial, the patients were not aware of which group they
were assigned to. The patients were only informed that
they would receive a periodontal surgical treatment that
potentially included cell products. This trial was a single-
center, randomized controlled study of 30 patients with 12
months of follow-up. In a phase I clinical trial, safety
assessments should be the primary outcome. The method-
ology in this study was designed to assess both safety and
efficacy because the use of PDL-derived cells for periodon-
tal therapy was previously reported several years ago [30].
Indeed, several groups worldwide have completed small-
scale pilot/feasibility studies that indicated no adverse re-
actions after local cell administration [29, 31]. Although
these studies did not have a randomized designed, the re-
ported safety of the treatment offers substantial evidence
to justify the use of cell-based periodontal therapy in the
clinic. To date, this study was one of the largest random-
ized controlled trials addressing the safety and effective-
ness of cell therapy in combination with GTR and bone
replacement for periodontitis. However, this study does
not deliver substantial evidence to confirm the safety of
cell-based periodontal therapy. Similar to the clinical use
of stem cells in the oral cavity (excluding the
periodontium) for bone regeneration [45, 46], cell-based
techniques in periodontal regenerative medicine should
be further investigated in more challenging clinical scenar-
ios with well-designed and standardized randomized con-
trolled trials. In addition, these therapies should be tested
in combination with bioactive molecules and new mate-
rials in an attempt to improve the final outcome. We plan
to design a phase II clinical trial for cell-based periodontal
therapy aimed at selecting more suitable scaffolding mate-
rials, determining appropriate cell doses, and providing
evidence for multicenter, randomized controlled trials.
Conclusions
Stem cell therapy is a promising new therapeutic avenue
that may enable the regeneration of lost periodontal tissue,
and regenerative dentistry is at the forefront of the transi-
tion from basic science research to the clinical recon-
structive arena. Although there are many issues that need
to be resolved before stem cell therapies become com-
monplace, clinicians should continue to monitor the pro-
gression of these technologies. The data obtained in this
study showed that autologous PDLSC-based treatment for
periodontal intrabony defects was safe; however, more
rigorous clinical trials are recommended to evaluate the
efficacy of this therapy. Future clinical endeavors in cell-
based periodontal therapy should identify more suitable
scaffolding materials and define safe and effective cell dos-
ing procedures based on well-designed, multicenter, ran-
domized controlled trials.
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